NCT00499720

Brief Summary

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
2 countries

65 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 9, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 11, 2007

Completed
Last Updated

August 2, 2011

Status Verified

July 1, 2011

First QC Date

July 9, 2007

Last Update Submit

July 29, 2011

Conditions

Keywords

Cystic FibrosisPseudomonas aeruginosaairway infectionAztreonam Lysine for Inhalation

Interventions

75 mg three times a day via inhalation for 28 days followed by 28 days off drug.

Eligibility Criteria

Age6 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 6 years of age
  • Subject has CF as diagnosed by one of the following:
  • Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test
  • Two well characterized genetic mutations in the CFTR gene
  • Abnormal nasal potential difference with accompanying symptoms characteristic of CF
  • At high risk for disease progression as defined by one of the following subject populations:
  • First Cohort Criteria:
  • Those who are wait listed or eligible for lung transplant based on FEV1 criteria. Patients who have a level of lung function impairment consistent with lung transplantation criteria, but who are ineligible for transplantation for other reasons, can enroll in this program; or
  • Completed participation in CP-AI-006 (through Visit 20). Subjects who withdraw from CP-AI-006 prior to completing all courses of AZLI and all study visits will not be eligible for this protocol.
  • Second Cohort Criteria:
  • Meets first cohort criteria
  • FEV1 ≤ 40% predicted at the time of consent
  • Third Cohort Criteria:
  • Meets first or second cohort criteria
  • FEV1 ≤ 50% predicted at the time of consent

You may not qualify if:

  • Subjects with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance with the protocol or dosing requirements
  • Subjects with hypersensitivity to any of the components of the drug product
  • Currently enrolled in another clinical trial
  • Pregnant or lactating females

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (65)

Unknown Facility

Birmingham, Alabama, 35233, United States

Location

Unknown Facility

Anchorage, Alaska, 99508, United States

Location

Unknown Facility

Phoenix, Arizona, 85016, United States

Location

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Los Angeles, California, 90027, United States

Location

Unknown Facility

Sacramento, California, 95819, United States

Location

Unknown Facility

San Francisco, California, 94115, United States

Location

Unknown Facility

San Francisco, California, 94143, United States

Location

Unknown Facility

Denver, Colorado, 80045, United States

Location

Unknown Facility

Denver, Colorado, 80206, United States

Location

Unknown Facility

Hartford, Connecticut, 06102, United States

Location

Unknown Facility

Hartford, Connecticut, 06106, United States

Location

Unknown Facility

Ft, Meyers, Florida, 33908, United States

Location

Unknown Facility

Gainesville, Florida, 32610, United States

Location

Unknown Facility

Orlando, Florida, 32803, United States

Location

Unknown Facility

St. Petersburg, Florida, 33701, United States

Location

Unknown Facility

Tampa, Florida, 33606, United States

Location

Unknown Facility

Boise, Idaho, 83712, United States

Location

Unknown Facility

Chicago, Illinois, 60302, United States

Location

Unknown Facility

Chicago, Illinois, 60614, United States

Location

Unknown Facility

Maywood, Illinois, 60153, United States

Location

Unknown Facility

Des Moines, Iowa, 50309, United States

Location

Unknown Facility

Wichita, Kansas, 67214, United States

Location

Unknown Facility

New Orleans, Louisiana, 70112, United States

Location

Unknown Facility

Boston, Massachusetts, 02111, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Detroit, Michigan, 48201, United States

Location

Unknown Facility

Minneapolis, Minnesota, 54404, United States

Location

Unknown Facility

Minneapolis, Minnesota, 55455, United States

Location

Unknown Facility

Columbia, Missouri, 65212, United States

Location

Unknown Facility

Kansas City, Missouri, 64108, United States

Location

Unknown Facility

Great Falls, Montana, 59405, United States

Location

Unknown Facility

Las Vegas, Nevada, 89107, United States

Location

Unknown Facility

Long Branch, New Jersey, 07740, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08901, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87131, United States

Location

Unknown Facility

Albany, New York, 12208-3479, United States

Location

Unknown Facility

Buffalo, New York, 14222, United States

Location

Unknown Facility

New Hyde Park, New York, 11040, United States

Location

Unknown Facility

New York, New York, 10011, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Syracuse, New York, 13210, United States

Location

Unknown Facility

Valhalla, New York, 10595, United States

Location

Unknown Facility

Chapel Hill, North Carolina, 27599-7220, United States

Location

Unknown Facility

Akron, Ohio, 44308, United States

Location

Unknown Facility

Cincinnati, Ohio, 45229, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Unknown Facility

Columbus, Ohio, 43205, United States

Location

Unknown Facility

Toledo, Ohio, 43605, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73104, United States

Location

Unknown Facility

Hershey, Pennsylvania, 17033, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19104, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19134, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

Sioux Falls, South Dakota, 57117, United States

Location

Unknown Facility

Memphis, Tennessee, 38103, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

Fort Worth, Texas, 76104, United States

Location

Unknown Facility

San Antonio, Texas, 78212, United States

Location

Unknown Facility

Salt Lake City, Utah, 84132-4701, United States

Location

Unknown Facility

Norfolk, Virginia, 23507, United States

Location

Unknown Facility

Portsmouth, Virginia, 23708, United States

Location

Unknown Facility

Richmond, Virginia, 23219, United States

Location

Unknown Facility

Seattle, Washington, 98195, United States

Location

Unknown Facility

San Juan, 366528, Puerto Rico

Location

MeSH Terms

Conditions

Cystic FibrosisPseudomonas Infections

Interventions

Inhalation

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

Respiratory MechanicsRespirationRespiratory Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

July 9, 2007

First Posted

July 11, 2007

Last Updated

August 2, 2011

Record last verified: 2011-07

Locations